| 5.05 -0.23 (-4.36%) | 09-11 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing therapeutic solutions for cancer and various other proliferative disorders. At the forefront of its pipeline are several investigational therapies: Fadraciclib, a cyclin-dependent kinase (CDK) inhibitor, is currently undergoing Phase 1/2 clinical evaluation. It's being assessed as a monotherapy for solid tumors and in combination with venetoclax for managing relapsed or refractory chronic lymphocytic leukemia. Another promising candidate is CYC140, a polo-like kinase inhibitor, also progressing through Phase 1/2 trials for advanced leukemias and various solid tumor types. The pipeline further features Sapacitabine, an orally available prodrug of CNDAC and a novel nucleoside analog. This compound is in Phase 1/2 clinical investigation for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Additionally, seliciclib, another CDK inhibitor, is being explored in investigator-sponsored trials (ISTs), specifically in Phase 2 for Cushing's disease and Phase 1/2 for advanced rheumatoid arthritis. Underscoring its commitment to research, Cyclacel maintains a clinical collaboration with the University of Texas MD Anderson Cancer Center. This partnership aims to assess the safety and effectiveness of three of its compounds in patients suffering from various hematological malignancies, including chronic lymphocytic leukemia, acute myeloid leukemia, myelodysplastic syndromes, and other advanced forms of leukemia. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.
Fri, 12 Sep 2025
Bio Green Med Solution, Inc. Completes Acquisition of Fitters Sdn. Bhd. to Diversify Business Portfolio - Quiver Quantitative
Tue, 06 May 2025
Cyclacel Pharmaceuticals Proposed Share Exchange - ARC Group
Fri, 25 Apr 2025
VivoSim Labs (VIVS) Stock Price, News & Analysis - Stock Titan
Thu, 24 Apr 2025
KIORA PHARMACEUTICALS (KPRX) Stock Price, News & Analysis - Stock Titan
Thu, 24 Apr 2025
In8Bio (INAB) Stock Price, News & Analysis - Stock Titan
Thu, 27 Feb 2025
Cyclacel Pharmaceuticals Announces Change in Control and Leadership with New CEO Appointment - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|